The FRA2 antibody targets FOS-related antigen 2 (Fra-2), a member of the FOS protein family, which includes c-Fos, Fra-1. and FosB. Fra-2 forms heterodimers with JUN family proteins to create the activator protein 1 (AP-1) transcription factor complex. AP-1 regulates genes involved in cell proliferation, differentiation, apoptosis, and stress responses. Unlike other FOS proteins, Fra-2 exhibits distinct regulatory mechanisms and tissue-specific roles. It is constitutively expressed in certain tissues, such as immune cells and epithelial tissues, and plays critical roles in embryonic development, bone homeostasis, and angiogenesis. Dysregulation of Fra-2 is implicated in pathological conditions, including cancer metastasis, fibrosis, and autoimmune diseases.
The FRA2 antibody is widely used in research to detect Fra-2 expression via techniques like Western blotting, immunohistochemistry, and immunofluorescence. It aids in studying Fra-2’s role in tumor progression, epithelial-mesenchymal transition (EMT), and inflammatory pathways. Studies highlight its involvement in modulating extracellular matrix remodeling and immune responses, making it a potential therapeutic target. Commercial FRA2 antibodies are typically validated for specificity across human, mouse, and rat samples, with applications in both basic research and clinical biomarker discovery. Understanding Fra-2’s dual roles in homeostasis and disease underscores its importance in cellular signaling research.